Type I Insulin-Like growth factor receptor

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The insulin-like growth factor (IGF) system has been implicated in many times of cancer. Upon ligand binding, the type I IGF receptor (IGF1R) transmembrane tyrosine kinase receptor is activated and serves to activate multiple downstream signaling targets. Multiple drugs have been developed to disrupt the function of this receptor, but to date the clinical trial results have been disappointing.

Original languageEnglish (US)
Title of host publicationCancer Therapeutic Targets
PublisherSpringer New York
Pages823-829
Number of pages7
Volume2-2
ISBN (Electronic)9781441907172
ISBN (Print)9781441907165
DOIs
StatePublished - Jan 1 2017

Keywords

  • Breast cancer
  • Clinical trials
  • Ewing's sarcoma
  • Fibroblast cells
  • Functional IGF1R
  • IGF-II
  • Monoclonal antibodies
  • Multianalyte molecular techniques
  • TKIs
  • Type I insulin-like growth factor receptor (IGF1R)
  • Tyrosine kinase inhibitors (TKIs)
  • mRNA expression and protein levels
  • ras/raf/MEK/MAPK and PI3K/Akt/mTORC1 signaling cascades

Fingerprint Dive into the research topics of 'Type I Insulin-Like growth factor receptor'. Together they form a unique fingerprint.

Cite this